Form 8-K REGENEREX PHARMA, INC. For: Sep 03
Tweet
Share
E-mailUNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported):
(Exact Name of Registrant as Specified in its Charter)
|
|
|||
(State or Other Jurisdiction of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
||
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c)) |
Securities registered pursuant to Section 12(b) of the Act: None.
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by check mark if the registrant has
elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section
13(a) of the Exchange Act.
|
SECTION 1 – REGISTRANT'S BUSINESS AND OPERATIONS
Item 1.01 - Entry into a Material Definitive Agreement
New Contract with Holista Colltech Ltd.
As part of the Company’s strategic advancement, Regenerex has entered into a licensing agreement with Holista Colltech Ltd. (“Holista”), a globally recognized producer of high-purity ovine collagen. This includes exclusive rights to use in wound care and distribution rights in the USA.
|
Regenerex Pharma, Inc. Enters Into Binding Supply and Development Agreement with Holista Colltech Ltd.
Sept 03, 2025- Las Vegas, NV- Regenerex Pharma, Inc (OTC: RGPX), a leading innovator in advanced wound closure systems for chronic wounds, today announced that it has entered into a binding supply and development agreement with Holista Colltech Ltd. of Perth, Australia.
Under terms of the agreement, Holista will exclusively manufacture and supply its proprietary ovine collagen, including its patented 300 kDa intact collagen and nano-collagen technologies, for Regenerex’s use in the development, clinical testing, and global distribution of advanced wound care products. The initial commercial focus will be the United States, with expansion into other global markets to follow.
Key Terms of the Agreement
- Exclusivity: Regenerex has exclusive worldwide rights to market Holista’s collagen products for wound care applications.
- Minimum Purchase Commitments: Regenerex is required to purchase a minimum of USD50,000 in 2025, scaling to USD3 million in 2026, USD6 million in 2027, and USD9 million annually from 2028 onwards.
- Clinical Development: Regenerex will conduct and fund clinical studies and regulatory approvals with the U.S. FDA and other relevant authorities.
- Joint Innovation: Both companies will collaborate on new applications of nano-collagen in advanced wound care, with joint ownership of any resulting intellectual property.
- Manufacturing: Holista’s ovine collagen will be drawn down from stocks from its manufacturing facility in Collie (WA) and nano-collagen to be produced in Malaysia, under international GMP and halal certification standards.
- Termination: The agreement runs for the life of the relevant patents and may be terminated earlier, including for convenience on 90 days’ notice or for breach, insolvency or by mutual agreement.
|
About Regenerex Pharma, Inc.
The Mission at Regenerex Pharma, Inc. is to provide the next historical solution in human health crises by solving chronic wound closure and reducing amputations resulting from the stalled healing process in chronic wounds. Regenerex’ s products treat diabetic foot ulcers, venous ulcers, burns, and pressure ulcers, and heal 95% of chronic wounds in 90 days or less using advanced proprietary wound care products, proven protocols, and proprietary EMR systems. More information about the Company may be found at regenerexpharmainc.com
About Holista Colltech Ltd.
Holista Colltech Ltd. is a global leader in the production of high-purity ovine collagen, leveraging Australia’s strict biosecurity standards and ethical sourcing practices. The company is committed to sustainable health innovations and the development of premium-grade natural ingredients for medical and consumer applications. More information about the Company may be found at holistaco.com
Notice regarding forward-looking statements
This press release contains forward-looking statements that may be subject to various risks and uncertainties. Such forward-looking statements are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and may include statements regarding our future financial performance or results of operations, including expected revenue growth. Unless otherwise required by law, we undertake no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise after the date of this press release. Additional information concerning risks and uncertainties that would cause actual results to differ materially from those projected or suggested in the forward-looking statements can be found in the reports that we have filed with the Securities and Exchange Commission.
Contact: Regenerex Pharma, Inc.
Company Ph: 877-761-RGPX (7479)
Investor Relations Ph: (305) 927-5191
Email: [email protected]
regenerexpharmainc.com
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, hereunto duly authorized.
|
REGENEREX PHARMA, INC. |
|
|
|
|
|
By: |
/s/ Greg Pilant |
Date: September 3, 2025 |
Name: |
Greg Pilant |
|
Title: |
Chief Executive Officer |
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HKSTP Leads Largest-Ever Hong Kong Delegation to BIO 2026 Showcasing Life and Health Tech Strength
- Infosys, ANA's Global CMO Growth Council, and LIONS Unveil the CMO AI Hub
- First Atlantic Nickel & Cobalt Produces High Grade Alloy Concentrate Up to 71.9% Nickel and 1.76% Cobalt from Its Pipestone XL Nickel-Cobalt Alloy Project, Using Its First-Ever ONSHORE MAX (Magnet
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
